Keyword: Merck

The Democratic Republic of Congo has approved four experimental treatments to help contain the Ebola outbreak, including one in development at Gilead.

Harbour BioMed licensed a midphase PD-L1 antibody from Kelun Biotech for development and commercialization outside of Greater China.

Merck & Co. and Geisinger are in talks with health IT firms that could help take their two new EHR apps to market.

CAR-T player Cellectis poached a Novartis exec; GSK recruited a CFO to spearhead cost-cutting; Thomas Hughes leaves Zafgen to lead Navitor; and more.

Agilent’s PD-L1 assay was expanded in Europe to help guide first-line Keytruda treatment in urothelial carcinoma.

Merck and HitGen upsized their licensing agreement to a full discovery collaboration, screening DNA-encoded libraries of billions of small molecules.

As it tussles over licensing checks and tries to gain a reprieve, AZ quietly announced that selumetinib has once again missed the mark in a cancer test.

The data link Merck’s doravirine to a higher rate of viral suppression than a combination of antiretroviral drugs from AbbVie and Johnson & Johnson.

Biogen and Eisai’s phase 2 Alzheimer’s trial has re-emerged, slowing clinical symptom decline and reducing amyloid plaque accumulation in the brain.

Bioelectronic medicine developer electroCore is going public with a $78 million IPO, listing 5.2 million shares of common stock at $15.00 per share.